HIV Prevention Drug - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from the US regulator.

Uncategorized

Gilead’s Yeztugo drug for HIV prevention in adults gets FDA nod

HQ Team June 19, 2025: Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from.

by HealthQuill
June 19, 2025
0 Comments

Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention of HIV.

Drugs Health Pharma

Gilead signs six global pacts to make, sell generic HIV preventive drug

Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.

by HealthQuill
October 3, 2024
0 Comments

About Us

Contact Info

Follow Us

Gilead’s Yeztugo drug for HIV prevention in adults gets FDA nod

Gilead signs six global pacts to make, sell generic HIV preventive drug